Quick Summary Want to plan and execute seamless cloud transitions across complex enterprise environments? Explore the top 7 cloud migration tools for CIOs in 2026 that help assess workloads, automate ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Bristol Myers Squibb has ended the week with an agreement to buy Orbital Therapeutics – a developer of in vivo cell therapies – for $1.5 billion in cash. Cambridge, Massachusetts-based Orbital is ...

Sanofi is reported to be preparing a move to take control of US biotech Ocular Therapeutix, after an initial bid was rejected last year. That is according to French newspaper La Lettre, which said ...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...

OCUL is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has decreased $0.20 since the market last closed. This is a 2.10% ...

OCUL is trading in the middle of its 52-week range and below its 200-day simple moving average. Price change The price of OCUL shares has decreased $0.18 since the market last closed. This is a 1.89% ...

Mondas are a cyber security consultancy leveraging the speed and scale of automation technologies to enhance your security capabilities. We help both in-house security teams and MSSPs to rapidly adopt ...

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes ...